Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS for multiple sclerosis while capitalizing on the commercial success of unbuzzd, a product that accelerates alcohol metabolism. In a recent appearance on the BioMedWire Podcast, Executive Co-Chairman and Co-Founder Anthony Durkacz detailed the company's strategy for Lucid-MS, which aims to address mobility damage associated with MS. The company has filed an investigational new drug application for a Phase 2 clinical trial, marking a potential first administration of the candidate to human MS patients.
Durkacz emphasized that Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The Phase 2 trial represents a critical milestone, as it could provide the first clinical evidence of the drug's efficacy in humans. Quantum BioPharma is also exploring broader applications of its platform in neurodegenerative and metabolic disorders.
Alongside its clinical pipeline, Quantum BioPharma is leveraging unbuzzd, a commercially available product designed to accelerate alcohol metabolism. The company invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI, as of March 31, 2026, and is entitled to royalty payments of 7% of unbuzzd sales until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
Durkacz highlighted that the unbuzzd strategy provides immediate revenue streams to support clinical development. This dual approach—combining high-risk pharmaceutical development with a market-ready consumer product—differentiates Quantum BioPharma from many biotech firms. The company's focus on neurodegenerative, metabolic, and alcohol-misuse conditions aligns with significant unmet medical needs.
For more details on the podcast discussion, the full article is available at https://ibn.fm/IWnPQ. Additional information about Quantum BioPharma and its news can be found in the company's newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. The company undertakes no obligation to update these statements unless required by law.
